H.U. Group Holdings, Inc.

Established in 1950 and headquartered in Tokyo, Japan, H.U. Group Holdings, Inc. (formerly Miraca Holdings Inc. until its rebranding in July 2020) provides an extensive array of laboratory testing products and services through its subsidiaries across Japan. The company delivers diagnostic testing and associated services to medical facilities, supports self-medication initiatives, and conducts testing for food, environmental samples, and cosmetic products. Additionally, it offers testing solutions tailored for corporate health insurance programs. The group is deeply involved in the research, development, manufacturing, and commercialization of in vitro diagnostic devices. Its product lineup features the LUMIPULSE, an automated chemiluminescent enzyme immunoassay system that supplies reagents for the detection of infectious diseases, various cancers, and lifestyle-related conditions to medical institutions and diagnostic centers. H.U. Group also produces the ESPRINE series of rapid diagnostic kits for ailments such as influenza, hepatitis B, and the novel coronavirus, alongside supplying essential ingredients for test drugs. Beyond diagnostics, the company offers crucial support services for hospital administration, including assistance during surgical and endoscope procedures, inspection and maintenance of medical equipment, and in-hospital logistics and transportation management. Furthermore, it addresses the elderly care market by renting and selling specialized equipment and supplies, and by providing in-home nursing care services.

產業

Medical - Diagnostics & Research

部門

Healthcare

總部

JP

執行長

Goki Ishikawa

上市以來

2001年1月1日

僱員

5,157

Established in 1950 and headquartered in Tokyo, Japan, H.U. Group Holdings, Inc. (formerly Miraca Holdings Inc. until its rebranding in July 2020) provides an extensive array of laboratory testing products and services through its subsidiaries across Japan. The company delivers diagnostic testing and associated services to medical facilities, supports self-medication initiatives, and conducts testing for food, environmental samples, and cosmetic products. Additionally, it offers testing solutions tailored for corporate health insurance programs. The group is deeply involved in the research, development, manufacturing, and commercialization of in vitro diagnostic devices. Its product lineup features the LUMIPULSE, an automated chemiluminescent enzyme immunoassay system that supplies reagents for the detection of infectious diseases, various cancers, and lifestyle-related conditions to medical institutions and diagnostic centers. H.U. Group also produces the ESPRINE series of rapid diagnostic kits for ailments such as influenza, hepatitis B, and the novel coronavirus, alongside supplying essential ingredients for test drugs. Beyond diagnostics, the company offers crucial support services for hospital administration, including assistance during surgical and endoscope procedures, inspection and maintenance of medical equipment, and in-hospital logistics and transportation management. Furthermore, it addresses the elderly care market by renting and selling specialized equipment and supplies, and by providing in-home nursing care services.

產業

Medical - Diagnostics & Research

部門

Healthcare

總部

JP

執行長

Goki Ishikawa

上市以來

2001年1月1日

僱員

5,157